Safety of long-term monthly cycles of methylprednisolone in combination with interferon β-1a IM in treatment-naive early relapsing-remitting multiple sclerosis patients in the MECOMBIN trial

被引：0
|
作者：
Ravnborg, M.
Sorensen, P. S.
Andersson, M.
Celius, E. Gulowsen
Jongen, P.
Batholome, E.
Elovaara, I.
Beer, K.
Sperling, B.
机构：
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S243 / S243
页数：1
相关论文
共 50 条
  • [1] Monthly cycles of methylprednisolone in combination with interferon β-1a IM are efficacious in the treatment of early relapsing-remitting multiple sclerosis. The MECOMBIN study
    Ravnborg, M.
    Sorensen, P. S.
    Andersson, M.
    Celius, E. Gulowsen
    Jongen, P.
    Bartholome, E.
    Elovaara, I.
    Beer, K.
    Constantinescu, C.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S14 - S14
  • [2] Long-term benefits of early and high douses of interferon β-1a treatment in relapsing-remitting multiple sclerosis
    Chofflon, M
    Ben-Amor, AF
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2002, 104 (03) : 244 - 248
  • [3] Long-term cost effectiveness of interferon-β-1a in the treatment of relapsing-remitting multiple sclerosis -: An econometric model
    Lepen, C
    Coyle, P
    Vollmer, T
    Blumhardt, L
    Lilliu, H
    Beresniak, A
    CLINICAL DRUG INVESTIGATION, 2003, 23 (09) : 571 - 581
  • [4] Early prediction of the long-term response to interferon beta in relapsing-remitting multiple sclerosis patients
    Schmit, E.
    Gourraud, P. A.
    Couturier, N.
    Le Page, E.
    Vukusic, S.
    Debouverie, M.
    Defer, G. L.
    Lebrun, C.
    Frangoulis, B.
    Achiti, J.
    Merle, H.
    Edan, G.
    Fontaine, B.
    Clanet, M.
    Brassat, D.
    MULTIPLE SCLEROSIS, 2007, 13 : S58 - S59
  • [5] Methylprednisolone as add-on to Interferon-β-1a in treatment naive relapsing-remitting multiple sclerosis (RRMS) patients reduces the annualized relapse rate
    Sorensen, P. S.
    Ravnborg, M.
    Andersson, M. L.
    Elovaara, I.
    Jongen, P.
    Constantinescu, C.
    Beer, K.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S202 - S202
  • [6] Clinical predictors of disability in treatment-naive relapsing-remitting multiple sclerosis patients
    Ivaniuk, A.
    Solodovnikova, I.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 921 - 921
  • [7] Successful Long-Term Treatment of Relapsing-Remitting Multiple Sclerosis with Interferon β-1b
    Schmidt, S.
    AKTUELLE NEUROLOGIE, 2012, 39 : S22 - S23
  • [8] Long-term adherence to interferon β therapy in relapsing-remitting multiple sclerosis
    Portaccio, E.
    Zipoli, V.
    Siracusa, G.
    Sorbi, S.
    Amato, M. P.
    EUROPEAN NEUROLOGY, 2008, 59 (3-4) : 131 - 135
  • [9] Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial
    Ozakbas, Serkan
    Cinar, Bilge Piri
    Kosehasanogullari, Gorkem
    Kahraman, Turhan
    Oz, Didem
    Kursun, Behice Bircan
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2017, 160 : 69 - 72
  • [10] Azathioprine and interferon β1a in relapsing-remitting multiple sclerosis patients:: Increasing efficacy of combined treatment
    Lus, G
    Romano, F
    Scuotto, A
    Accardo, C
    Cotrufo, R
    EUROPEAN NEUROLOGY, 2004, 51 (01) : 15 - 20
12345